

Eurobio Scientific reached agreement to acquire 100% of Dutch Transplant Diagnostics firm, GenDx

The Netherlands, UTRECHT, August, 17th 2022

The Paris, France based Eurobio Scientific (“Eurobio”) has reached agreement to acquire all outstanding shares of GenDx (the “Company”) for an amount of 135m€ (net of adjusted cash) to be paid in cash at closing to its current shareholders.

GenDx will continue its activities in both its Utrecht headquarters and its North American office, located in Chicago, IL. The GenDx portfolio will be continued and supported by GenDx’s existing mature sales and global distributor network. Only minor adjustments are expected to optimize the distribution channel, such that it matches with the strategy of Eurobio and its existing portfolio companies.

Founder Wietse Mulder PhD, CEO and cofounder of GenDx, will continue as CEO of GenDx and member of the board. He is appointed for an initial term of two years. Co-founder, Erik Rozemuller PhD, Senior Scientist Bioinformatics, will transition to a consultancy role to support the R&D team as required.

Rozemuller commented: “Over the past years, I was proud to experience the developments within GenDx. With our great team of highly motivated people we will continue to succeed in creating the best products, including broadening our reach beyond the field of HLA typing. I see the current transaction as fully aligned with GenDx’s values as it enables even more opportunities to serve transplant patients to the best of our capabilities.”

Mulder commented: “We are excited to continue GenDx’s activities under the Eurobio Scientific umbrella. With Denis Fortier, co-CEO, at the helm, I found a matching entrepreneurial spirit. I am confident that Eurobio is a good home for GenDx to secure the support of our customers in the field of transplant diagnostics and to align with our global distributor network. Furthermore, it will allow our employees to continue their superb work in R&D, operations, logistics, regulatory affairs, sales, marketing, support and, importantly, our renowned educational activities.”

ad tempus vitae

This transaction is the result of an intensive project called *ad tempus vitae* (“ATV”), meaning ‘to prolong life’. This term carries double meaning. Firstly, it refers to GenDx’s offering of products and services aimed at prolonging the life of transplant patients. Secondly, it refers to prolonging the life of the Company, GenDx, by securing the legacy of the founders, which has been built over the last 18 years. The GenDx ATV project was coordinated by Jason Arnold and his London-based M&A advisory team at William Blair, with legal support from Herke van Hulst, Wouter Kok and team at Osborne & Clarke in Amsterdam. RSM provided vendor financial due diligence services to the Company.

Fostered by the *adagium* of 'meaningful entrepreneurship', Mulder and Rozemuller will establish a foundation, funded by proceeds of this transaction, aimed at supporting educational and R&D activities in the field of transplantation.

=====

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 148 employees and three production units based in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands.

Eurobio Scientific's reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the "Pépites et Territoires" by AXA & NextStage AM investment program, managed by NextStage AM.

For more information, please visit : www.eurobio-scientific.com

The company is publicly listed on the Euronext Growth market in Paris Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.

Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP

About GenDx

Genome Diagnostics B.V., also known as GenDx, is a Dutch company specialized in molecular diagnostics, focused on development, production and sales of innovative assays and analysis software for transplant and companion diagnostics. To support GenDx's USA customers it has an office near O'Hare airport, Chicago, IL.

GenDx specializes in HLA sequencing-based typing strategies and offers reagents and software for both Sanger and NGS approaches. As one of the pioneering companies in the HLA field with Sanger approaches, GenDx started offering NGS strategies in 2013, consisting of NGSgo[®] reagents and the software package NGSengine[®] for various NGS platforms. Additionally, GenDx offers products for chimerism monitoring by qPCR and - launched recently - by NGS: NGStrack[®] & TRKengine[®]. Last month a license was obtained from California based company Dovetail Genomics (now part of Cantata Bio) allowing GenDx to explore their hybrid capture approach enabling HLA genotyping and ultimately haplotyping of HLA genes. Furthermore, GenDx obtained a worldwide license from Medical College Wisconsin (MCW) for their patented method to detect donor specific cell free DNA (cfDNA) in pediatric patients that have undergone a heart transplant.

Thanks to its extensive in-house expertise, GenDx also offers custom laboratory services for basic and clinical research organizations. GenDx Education organizes dedicated HLA

sequence-based typing and chimerism monitoring training courses worldwide on a regular basis. The training courses are applicable for anyone working in tissue typing or research laboratories, blood banks, and donor registries.

GenDx is based at the Utrecht Science Park (USP), the Netherlands, and was founded in 2005 by Erik Rozemuller PhD and Wietse Mulder PhD as a spinoff of UMC Utrecht and helped by a 2002 Biopartner First Stage Grant. In 2019, Ampersand Capital Partners acquired a minority stake in the Company.

Currently, GenDx is located at USP in two opposite buildings: Alexander Numan and Androclus. In Q1-2023, GenDx will expand its footprint in A. Numan building by additionally leasing the top three floors of that building. The activities in Androclus will gradually be migrated to Numan building. Total facilities will encompass more than 3000 m².

For further information about GenDx visit www.GenDx.com.

GenDx

Yalelaan 48
3584 CM Utrecht
The Netherlands
Office: +31 30 252 3799
E-mail: info@gendx.com

Eurobio Scientific

7 avenue de Scandinavie
ZA de Courtaboeuf
91940 Les Ulis
France
Office: +33 1 69 79 64 80

Contact GenDx

Wietse Mulder PhD, CEO
Email: w.mulder@gendx.com
Phone: +31 6 51265864

Maarten Penning PhD
Chief Technology Officer and deputy CEO
Email: m.penning@gendx.com
Phone: +31 613367881

Contact Eurobio Scientific

Denis Fortier, co-CEO
Email : d.fortier@eurobio-scientific.com
Phone : +33 1 69 79 64 80

Hervé Duchesne de Lamotte MBA
Chief Financial Officer
Email : h.delamotte@eurobio-scientific.com
Phone : +33 1 69 79 64 80

SBTEngine[®], SBTExcellerator[®], NGSgo[®], NGStrack[®], NGSengine[®] TRKengine[®] and GenDx are registered trademarks of Genome Diagnostics B.V.
